Published in Isr J Psychiatry Relat Sci on January 01, 2005
The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs (2014) 1.18
Clozapine-induced bowel infarction: a case report. Psychiatry (Edgmont) (2009) 1.07
Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry (2009) 0.90
Rare and very rare adverse effects of clozapine. Neuropsychiatr Dis Treat (2015) 0.88
A case report of clozapine-induced severe gastrointestinal hypomotility. Prim Care Companion CNS Disord (2014) 0.76
Novel olanzapine analogues presenting a reduced H1 receptor affinity and retained 5HT2A/D2 binding affinity ratio. BMC Pharmacol (2012) 0.76
Acute camptocormia induced by olanzapine: a case report. J Med Case Rep (2010) 0.75
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull (2009) 4.69
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry (2007) 2.26
Improvement in psychotic symptoms after a gluten-free diet in a boy with complex autoimmune illness. Am J Psychiatry (2015) 2.01
Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug Alcohol Depend (2010) 1.39
Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population. Schizophr Bull (2009) 1.39
Fluoxetine augmentation of haloperidol in chronic schizophrenia. J Clin Psychopharmacol (2003) 1.37
Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem (2009) 1.28
Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology (2011) 1.20
Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration. Clin Chem (2010) 1.19
Neurologic and psychiatric manifestations of celiac disease and gluten sensitivity. Psychiatr Q (2012) 1.13
The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol (2003) 1.10
Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study. Schizophr Res (2013) 1.08
Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr Res (2011) 1.08
Comparison of clozapine use in Maryland and in Victoria, Australia. Psychiatr Serv (2005) 1.05
A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol (2012) 1.04
Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharmacol Bull (2007) 1.01
Diagnostic criteria for cannabis withdrawal syndrome. Drug Alcohol Depend (2011) 1.00
Increased prevalence of transglutaminase 6 antibodies in sera from schizophrenia patients. Schizophr Bull (2012) 0.95
Case report on the management of depression in schizoaffective disorder, bipolar type focusing on lithium levels and measurement-based care. J Nerv Ment Dis (2011) 0.95
Elevated gliadin antibody levels in individuals with schizophrenia. World J Biol Psychiatry (2013) 0.95
Novel factor-based symptom scores in treatment resistant schizophrenia: implications for clinical trials. Neuropsychopharmacology (2002) 0.94
A gluten-free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies. Schizophr Res (2012) 0.92
Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin Neuropharmacol (2005) 0.92
Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry (2003) 0.91
Antagonist-elicited cannabis withdrawal in humans. J Clin Psychopharmacol (2011) 0.91
Quetiapine at high doses for the treatment of refractory schizophrenia. Schizophr Res (2008) 0.90
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr Res (2011) 0.89
Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry (2006) 0.88
Tobacco craving in smokers with and without schizophrenia. Schizophr Res (2010) 0.87
Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Δ(9)-tetrahydrocannabinol administration. Clin Chem (2011) 0.86
Bone mineral density and osteoporosis risk in older patients with schizophrenia. J Clin Psychopharmacol (2011) 0.86
Cervical cancer screening and acute care visits among Medicaid enrollees with mental and substance use disorders. Psychiatr Serv (2012) 0.85
Clinical characteristics of heavy and non-heavy smokers with schizophrenia. Schizophr Res (2012) 0.85
Around-the-clock oral THC effects on sleep in male chronic daily cannabis smokers. Am J Addict (2013) 0.84
Cannabis withdrawal in chronic cannabis users with schizophrenia. J Psychiatr Res (2012) 0.84
Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders. J Psychiatr Res (2012) 0.84
Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology (2010) 0.83
Circumstances of suicide among individuals with schizophrenia. Schizophr Res (2002) 0.83
Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr Res (2011) 0.83
Role of chronic stress and depression in periodontal diseases. Periodontol 2000 (2014) 0.83
A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia. J Clin Psychopharmacol (2017) 0.82
Tolerance to effects of high-dose oral δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers. J Anal Toxicol (2012) 0.82
Reduced arterial compliance in patients with psychiatric diagnoses. Schizophr Res (2012) 0.82
The effects of galantamine on psychopathology in chronic stable schizophrenia. Clin Neuropharmacol (2009) 0.81
Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses (2011) 0.81
Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone. Clin Neuropharmacol (2003) 0.80
Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research. Schizophr Bull (2008) 0.80
Deaths from diabetic ketoacidosis after long-term clozapine treatment. Am J Psychiatry (2003) 0.80
Exercise program adherence using a 5-kilometer (5K) event as an achievable goal in people with schizophrenia. Biol Res Nurs (2010) 0.80
Prevalence of childhood physical and sexual abuse in veterans with psychiatric diagnoses. J Nerv Ment Dis (2013) 0.79
Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. Drug Alcohol Depend (2012) 0.79
Perception of depot antipsychotics by mental health professionals. J Psychiatr Pract (2003) 0.79
Psychotropic prescribing for acute inpatient admissions in patients with severe psychosis. J Clin Psychopharmacol (2004) 0.78
CB1 - cannabinoid receptor antagonist effects on cortisol in cannabis-dependent men. Am J Drug Alcohol Abuse (2011) 0.78
Cardiovascular disease in relation to weight in deceased persons with schizophrenia. Compr Psychiatry (2005) 0.78
Current status of antipsychotic treatment. Curr Drug Targets CNS Neurol Disord (2002) 0.77
The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use. J Dual Diagn (2012) 0.77
Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia. J Neuropsychiatry Clin Neurosci (2005) 0.76
Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: a disconnect of the striatal D2 occupancy story: case report. J Clin Psychopharmacol (2008) 0.76
The effects of clozapine and high-dose olanzapine on brain function in treatment-resistant schizophrenia: a case study. J Psychopharmacol (2004) 0.76
The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia. J Clin Psychopharmacol (2005) 0.76
Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine. J Clin Psychiatry (2003) 0.76
Evaluating sexual function in patients with treatment-resistant schizophrenia. Schizophr Res (2003) 0.76
Illicit drug use in heavy smokers with and without schizophrenia. Schizophr Res (2012) 0.76
The risk of suicide after clozapine discontinuation: Cause for concern. Ann Clin Psychiatry (2015) 0.75
T. Kishi and N. Iwata: Varenicline for smoking cessation in people with schizophrenia: systematic review meta-analysis. Eur Arch Psychiatry Clin Neurosci (2014) 0.75
Kynurenine and Tryptophan Levels in Patients With Schizophrenia and Elevated Antigliadin Immunoglobulin G Antibodies. Psychosom Med (2016) 0.75
Electrochemical study of the catechol-modified chitosan system for clozapine treatment monitoring. Langmuir (2014) 0.75
Olanzapine and risperidone. Am J Health Syst Pharm (2003) 0.75
Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection. J Cent Nerv Syst Dis (2011) 0.75
Comparison of clozapine response for inpatients in the research setting versus routine clinical practice. Psychiatr Q (2008) 0.75
Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol (2013) 0.75
Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis. J Clin Psychopharmacol (2007) 0.75
Anti-inflammatory Combination Therapy for the Treatment of Schizophrenia. J Clin Psychopharmacol (2020) 0.75
Cortisol response to buspirone in extended abstinent alcoholics. Alcohol Alcohol (2004) 0.75
The relationship of brain weight to body mass index (BMI) upon autopsy in young people with severe mental illness. Schizophr Res (2010) 0.75
A new blood-based diagnostic aid for schizophrenia. Psychiatr Serv (2011) 0.75